Clinical trials in multiple sclerosis
Clinical trials should fulfill standard criteria for methodological quality, assuring an objective estimate of treatment effects. The quality of clinical trials is now frequently evaluated according to the CONSORT statement. Currently, there are 14 FDA-approved disease-modifying therapies available for the treatment of relapsing-remitting multiple sclerosis.
Mar. 16, 2020